Investigational drug · Phase 2
Normal Saline along
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia, Neonatal Encephalopathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
207
Any phase or sponsor naming "Normal Saline along"
First trial start
2019
Jan 10, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Normal Saline along", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypoxic-Ischemic Encephalopathy
- Neonatal Asphyxia
- Neonatal Encephalopathy
- Acute Spinal Cord Injury
Largest trials
Live from ClinicalTrials.gov: studies naming "Normal Saline along" as an intervention, largest first.
- Efficacy Study of Different Analgesic Options in Kidney Stone Pain ManagementPivotal-lookingCompleted
Hamad Medical CorporationIndustry
NCT02187614 · 1,645 participants · Start Aug 2014 · Primary completion Feb 2015
Drug: Diclofenac; Morphine and 2 more · For: Renal Colic; Urinary Calculi
Sites: Doha, Qatar
- A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and AdultsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04886154 · 1,440 participants · Start Jun 14, 2021 · Primary completion Feb 2, 2024
Drug: MenACWY vaccine · For: Infections, Meningococcal
Sites: Colorado Springs, Colorado; Longmont, Colorado; Doral, Florida · 53 sites in all
- Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac SurgeryPivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05635227 · 1,200 participants (planned) · Start Nov 10, 2022 · Primary completion Dec 2027
Drug: Dexamethasone phosphate; Isotonic sodium chloride (0.9%) and 2 more · For: Coronary Artery Disease; Aortic Valve Disease
Sites: Copenhagen, Denmark
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03621670 · 1,196 participants · Start Jul 27, 2018 · Primary completion Dec 27, 2024
Drug: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ); Prevnar13 and 7 more · For: Infections, Meningococcal
Sites: Birmingham, Alabama; Fayetteville, Arkansas; Jonesboro, Arkansas · 57 sites in all
- Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery CatheterizationPivotal-lookingStatus unknown
Rajaie Cardiovascular Medical and Research CenterAcademic, hospital or other
NCT03755700 · 1,000 participants (planned) · Start Nov 1, 2018 · Primary completion Dec 31, 2019
Drug: Vitamin E; N-acetyl cysteine and 3 more · For: Coronary Artery Disease; Coronary Artery Angiography; Coronary Catheterization and 3 more
Sites: Tehran, Iran
BayerBayer (BAYRY)
NCT02043678 · 806 participants · Start Mar 30, 2014 · Primary completion Feb 15, 2018
Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Matching placebo (normal saline) and 2 more · For: Prostatic Neoplasms
Sites: Anchorage, Alaska; Tucson, Arizona; Oceanside, California · 163 sites in all
- Tranexamic Acid for Acute Upper Gastrointestinal Bleed in CirrhosisPivotal-lookingStatus unknown
Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
NCT04489108 · 600 participants (planned) · Start Nov 5, 2020 · Primary completion Apr 30, 2022
Drug: Tranexamic acid · For: Liver Cirrhosis
Sites: New Delhi, India
- SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HFPivotal-lookingStatus unknown
University of PalermoAcademic, hospital or other
NCT06442280 · 544 participants (planned) · Start Jun 2024 · Primary completion Jan 31, 2026
Drug: Dapagliflozin tablet; Hypertonic Saline Solution, 1 Ml and 1 more · For: Heart Failure Acute; Diabetes Type 2; Heart Failure With Reduced Ejection Fraction and 1 more
- The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary HyperinflammationPivotal-lookingStatus unknown
Hadassah Medical OrganizationAcademic, hospital or other
NCT04377750 · 500 participants (planned) · Start Apr 8, 2020 · Primary completion Apr 29, 2020
Drug: Tocilizumab · For: Covid19 Pneumonia
Sites: Jerusalem, Israel; Ashkelon, Israel; Holon, Israel · 4 sites in all
- Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and OlderPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT04537208 · 441 participants · Start Sep 3, 2020 · Primary completion Nov 19, 2021
Drug: CoV2 preS dTM-AF03 (low-dose); CoV2 preS dTM-AF03 (high-dose) and 4 more · For: COVID-19 (Healthy Volunteers)
Sites: Birmingham, Alabama; Rolling Hills Estates, California; Hollywood, Florida · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypoxic-Ischemic Encephalopathy
- RLS-0071Phase 33 trials
ReAlta Life Sciences, Inc. · Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Hypoxic-Ischemic Encephalopathy, Steroid Refractory GVHD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.